Please use this identifier to cite or link to this item:
Title: Cognitive composites for genetic frontotemporal dementia: GENFI-Cog
Authors: Poos, JM
Moore, KM
Nicholas, J
Russell, LL
Peakman, G
Convery, RS
Jiskoot, LC
van der Ende, E
van den Berg, E
Papma, JM
Seelaar, H
Shoesmith, C
Bartha, R
Rademakers, R
Wilke, C
Karnarth, HO
Bender, B
Bruffaerts, R
Vandamme, P
Genetic FTD Initiative (GENFI)
Pijnenburg, YAL
Moreno, F
Sanchez-Valle, R
Borroni, B
Laforce, R
Masellis, M
Tartaglia, C
Graff, C
Galimberti, D
Rowe, JB
Finger, E
Synofzik, M
Vandenberghe, R
de Mendonça, A
Tiraboschi, P
Santana, I
Ducharme, S
Butler, C
Gerhard, A
Levin, J
Danek, A
Otto, M
Le Ber, I
Pasquier, F
van Swieten, JC
Rohrer, JD
Bouzigues, A
Rossor, MN
Fox, NC
Warren, JD
Bocchetta, M
Swift, IJ
Shafei, R
Heller, C
Todd, E
Cash, D
Woollacott, I
Zetterberg, H
Nelson, A
Guerreiro, R
Bras, J
Thomas, DL
Mead, S
Meeter, L
Panman, J
van Minkelen, R
Barandiaran, M
Indakoetxea, B
Gabilondo, A
Tainta, M
Gorostidi, A
Zulaica, M
Díez, A
Villanua, J
Borrego-Ecija, S
Olives, J
Lladó, A
Balasa, M
Antonell, A
Bargallo, N
Premi, E
Gazzina, S
Gasparotti, R
Archetti, S
Black, S
Mitchell, S
Rogaeva, E
Freedman, M
Keren, R
Tang-Wai, D
Thonberg, H
Öijerstedt, L
Andersson, C
Jelic, V
Arighi, A
Fenoglio, C
Scarpini, E
Fumagalli, G
Cope, T
Timberlake, C
Rittman, T
Keywords: frontotemporal dementia;cognition;neuropsychology;composite score;language;attention;executive function;memory;social cognition
Issue Date: 19-Jan-2022
Publisher: BioMed Central (part of Springer Nature)
Citation: Poos, J.M. et al. on behalf of the Genetic FTD Initiative (GENFI) (2022) 'Cognitive composites for genetic frontotemporal dementia: GENFI-Cog', Alzheimer's Research and Therapy, 14 (1), 10, pp. 1 - 12. doi: 10.1186/s13195-022-00958-0.
Abstract: Copyright © The Author(s) 2022. Background: Clinical endpoints for upcoming therapeutic trials in frontotemporal dementia (FTD) are increasingly urgent. Cognitive composite scores are often used as endpoints but are lacking in genetic FTD. We aimed to create cognitive composite scores for genetic frontotemporal dementia (FTD) as well as recommendations for recruitment and duration in clinical trial design. Methods: A standardized neuropsychological test battery covering six cognitive domains was completed by 69 C9orf72, 41 GRN, and 28 MAPT mutation carriers with CDR® plus NACC-FTLD ≥ 0.5 and 275 controls. Logistic regression was used to identify the combination of tests that distinguished best between each mutation carrier group and controls. The composite scores were calculated from the weighted averages of test scores in the models based on the regression coefficients. Sample size estimates were calculated for individual cognitive tests and composites in a theoretical trial aimed at preventing progression from a prodromal stage (CDR® plus NACC-FTLD 0.5) to a fully symptomatic stage (CDR® plus NACC-FTLD ≥ 1). Time-to-event analysis was performed to determine how quickly mutation carriers progressed from CDR® plus NACC-FTLD = 0.5 to ≥ 1 (and therefore how long a trial would need to be). Results: The results from the logistic regression analyses resulted in different composite scores for each mutation carrier group (i.e. C9orf72, GRN, and MAPT). The estimated sample size to detect a treatment effect was lower for composite scores than for most individual tests. A Kaplan-Meier curve showed that after 3 years, ~ 50% of individuals had converted from CDR® plus NACC-FTLD 0.5 to ≥ 1, which means that the estimated effect size needs to be halved in sample size calculations as only half of the mutation carriers would be expected to progress from CDR® plus NACC FTLD 0.5 to ≥ 1 without treatment over that time period. Discussion: We created gene-specific cognitive composite scores for C9orf72, GRN, and MAPT mutation carriers, which resulted in substantially lower estimated sample sizes to detect a treatment effect than the individual cognitive tests. The GENFI-Cog composites have potential as cognitive endpoints for upcoming clinical trials. The results from this study provide recommendations for estimating sample size and trial duration.
Description: Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Supplementary Information: Additional file 1 of Cognitive composites for genetic frontotemporal dementia: GENFI-Cog: Table S1. Number of control data available in each language per cognitive test. Table S2. Parameters included in the sample size calculations. Table S3. Participants characteristics and neuropsychological test results per CDR® plus NACC FTLD global score. Table S4. Number of mutation carriers that progressed on the CDR® plus NACC FTLD. Figure S1. STROBE flowchart. Available at: .
Other Identifiers: ORCID iD: Martina Bocchetta
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © The Author(s) 2022. Rights and permissions: Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.1.19 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons